Michael O'Dwyer to Leukemia, Lymphocytic, Chronic, B-Cell
This is a "connection" page, showing publications Michael O'Dwyer has written about Leukemia, Lymphocytic, Chronic, B-Cell.
Connection Strength
0.889
-
IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Adv. 2020 10 27; 4(20):5093-5106.
Score: 0.168
-
Biclonal lymphoproliferative disorders: another association with NOTCH1-mutated chronic lymphocytic leukaemias. Ir J Med Sci. 2021 Aug; 190(3):1087-1094.
Score: 0.168
-
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807.
Score: 0.153
-
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. Br J Haematol. 2018 09; 182(5):654-669.
Score: 0.143
-
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. Leuk Lymphoma. 2018 06; 59(6):1338-1347.
Score: 0.136
-
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17; 373(25):2425-37.
Score: 0.120